Search research articles
Contact Us
Filters
Showing results (151-160 of 204) with videos related to
Page
of 21
Sort By:
Scientific Reports
|
February 26, 2021
A bladder cancer patient-derived xenograft displays aggressive growth dynamics in vivo and in organoid culture
Elise Y Cai, Jose Garcia, Yuzhen Liu, et al.
Clinical Genitourinary Cancer
|
May 19, 2024
Adjuvant Chemotherapy and Survival After Radical Cystectomy in Histologic Subtype Bladder Cancer
Elizabeth L Koehne, Dimitra R Bakaloudi, Fady Ghali, et al.
Cancer
|
May 5, 2016
Prostate tumor DNA methylation is associated with cigarette smoking and adverse prostate cancer outcomes
Irene M Shui, Chao-Jen Wong, Shanshan Zhao, et al.
Clinical Genitourinary Cancer
|
June 21, 2023
Metastatic Bladder Cancer Expression and Subcellular Localization of Nectin-4 and Trop-2 in Variant Histology: A Rapid Autopsy Study
Fady Ghali, Funda Vakar-Lopez, Martine P Roudier, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 1, 2016
Epigenome-Wide Tumor DNA Methylation Profiling Identifies Novel Prognostic Biomarkers of Metastatic-Lethal Progression in Men Diagnosed with Clinically Localized Prostate Cancer
Shanshan Zhao, Milan S Geybels, Amy Leonardson, et al.
Molecular Oncology
|
February 2, 2017
Gene expression panel predicts metastatic-lethal prostate cancer outcomes in men diagnosed with clinically localized prostate cancer
Rohina Rubicz, Shanshan Zhao, Jonathan L Wright, et al.
The Journal of Urology
|
October 13, 2021
Patients with Muscle-Invasive Bladder Cancer with Nonluminal Subtype Derive Greatest Benefit from Platinum Based Neoadjuvant Chemotherapy
Yair Lotan, Joep J de Jong, Vinnie Y T Liu, et al.
Urologic Oncology
|
December 9, 2019
Validation of a neuroendocrine-like classifier confirms poor outcomes in patients with bladder cancer treated with cisplatin-based neoadjuvant chemotherapy
Petros Grivas, Tarek A Bismar, Aijai S Alva, et al.
Urologic Oncology
|
April 17, 2018
Mechanistic target of rapamycin (MTOR) protein expression in the tumor and its microenvironment correlates with more aggressive pathology at cystectomy
Brian R Winters, Funda Vakar-Lopez, Lisha Brown, et al.
The Prostate
|
June 30, 2018
A five-CpG DNA methylation score to predict metastatic-lethal outcomes in men treated with radical prostatectomy for localized prostate cancer
Shanshan Zhao, Amy Leonardson, Milan S Geybels, et al.
Page
of 21
Search research articles
Search
Showing results (151-160 of 204) with videos related to
Sort By:
Page
of 21
Scientific Reports
|
February 26, 2021
A bladder cancer patient-derived xenograft displays aggressive growth dynamics in vivo and in organoid culture
Elise Y Cai, Jose Garcia, Yuzhen Liu, et al.
Clinical Genitourinary Cancer
|
May 19, 2024
Adjuvant Chemotherapy and Survival After Radical Cystectomy in Histologic Subtype Bladder Cancer
Elizabeth L Koehne, Dimitra R Bakaloudi, Fady Ghali, et al.
Cancer
|
May 5, 2016
Prostate tumor DNA methylation is associated with cigarette smoking and adverse prostate cancer outcomes
Irene M Shui, Chao-Jen Wong, Shanshan Zhao, et al.
Clinical Genitourinary Cancer
|
June 21, 2023
Metastatic Bladder Cancer Expression and Subcellular Localization of Nectin-4 and Trop-2 in Variant Histology: A Rapid Autopsy Study
Fady Ghali, Funda Vakar-Lopez, Martine P Roudier, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 1, 2016
Epigenome-Wide Tumor DNA Methylation Profiling Identifies Novel Prognostic Biomarkers of Metastatic-Lethal Progression in Men Diagnosed with Clinically Localized Prostate Cancer
Shanshan Zhao, Milan S Geybels, Amy Leonardson, et al.
Molecular Oncology
|
February 2, 2017
Gene expression panel predicts metastatic-lethal prostate cancer outcomes in men diagnosed with clinically localized prostate cancer
Rohina Rubicz, Shanshan Zhao, Jonathan L Wright, et al.
The Journal of Urology
|
October 13, 2021
Patients with Muscle-Invasive Bladder Cancer with Nonluminal Subtype Derive Greatest Benefit from Platinum Based Neoadjuvant Chemotherapy
Yair Lotan, Joep J de Jong, Vinnie Y T Liu, et al.
Urologic Oncology
|
December 9, 2019
Validation of a neuroendocrine-like classifier confirms poor outcomes in patients with bladder cancer treated with cisplatin-based neoadjuvant chemotherapy
Petros Grivas, Tarek A Bismar, Aijai S Alva, et al.
Urologic Oncology
|
April 17, 2018
Mechanistic target of rapamycin (MTOR) protein expression in the tumor and its microenvironment correlates with more aggressive pathology at cystectomy
Brian R Winters, Funda Vakar-Lopez, Lisha Brown, et al.
The Prostate
|
June 30, 2018
A five-CpG DNA methylation score to predict metastatic-lethal outcomes in men treated with radical prostatectomy for localized prostate cancer
Shanshan Zhao, Amy Leonardson, Milan S Geybels, et al.
Page
of 21